Loading
Loading
Research Overview
Single-chain derivative of the relaxin-2 B-chain; selective RXFP1 agonist that preserves anti-fibrotic signalling in cardiac, renal, and pulmonary tissues via collagen remodelling pathways while reducing the vasodilatory effects of full-length relaxin.
Overview
B7-33 was designed as a selective RXFP1 agonist that preserves the anti-fibrotic signalling of the relaxin-2 hormone while reducing its vasodilatory and blood-pressure-lowering properties. Full relaxin has demonstrated anti-fibrotic activity in preclinical models but causes significant haemodynamic effects that limit its therapeutic utility — B7-33's selective design aims to separate anti-fibrotic efficacy from cardiovascular side effects.
Preclinical research using B7-33 has examined fibrotic disease markers in cardiac, pulmonary, and renal tissue models. The compound is administered subcutaneously in animal studies and has been shown to activate RXFP1-mediated signalling cascades associated with extracellular matrix remodelling and collagen turnover.
B7-33 remains in very early preclinical stages with no published human safety or efficacy data. It represents a research tool for understanding RXFP1 biology and the role of the relaxin pathway in fibrotic disease rather than an established protocol compound. Community adoption is extremely limited.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, b7-33 has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Single-chain derivative of the relaxin-2 B-chain; selective RXFP1 agonist that preserves anti-fibrotic signalling in cardiac, renal, and pulmonary tissues via collagen remodelling pathways while reducing the vasodilatory effects of full-length relaxin.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.